BMS wins FDA nod for new Orencia jab; Court reinstates Lilly's Strattera patent;

@FiercePharma: Pfizer nutritionals unit on deck for auction. Could be a $10.5B deal. Item | Follow @FiercePharma

> Bristol-Myers Squibb got the FDA nod for a subcutaneous form of Orencia, the rheumatoid arthritis drug previously available in an IV formulation. Story

> Eli Lilly won its appeal of a lower-court ruling that invalidated a 2017 patent on the popular ADHD drug Strattera, halting several generics versions in their tracks, at least for now. Report

> Vanda Pharmaceuticals inked a licensing deal with Argentina's Biotoscana Farma to launch its antipsychotic drug Fanapt in that country. Vanda release

> The global market for antipsychotic drugs reached $24.2 billion in 2010, more than one-third of the business for central nervous system meds. Release

> Pfizer's India unit posted a 19% increase in quarterly profits on net sales of 24.2 billion rupees, or $54.8 million; full Pfizer results are due Tuesday. Item

> Bosnia's biggest drug company, Bosnalijek, saw profits rise 1.5% on a 6.6% surge in revenues to 52 million marka, or about $38 million. Article

> Pharma distributor AmerisourceBergen is scouting for potential acquisitions in the distribution and packaging-services businesses. More

Biotech News

@FierceBiotech: BDO: Biotechs continue to rein in R&D costs, focus on top prospects. Piece | Follow @FierceBiotech

@JohnCFierce: Teva Ph3 for laquinimod (MS) fails. But they're planning apps in any case. (hmmmm) Report | Follow @JohnCFierce

@RyanMFierce: More Biogen coverage to come after trip to Boston, but first catching up on pipeline priorities: Story $BIIB | Follow @RyanMFierce

@MaureenFierce: Big Pharma's cutbacks are small biotechs' opportunity. Story via Seeking Alpha | Follow @MaureenFierce

> Biotechs show keen interest in new drugs for Down Syndrome. Article

> Teva's oral MS drug trips (again) in blockbuster Ph3 developmnt race. More

> Another setback for RNAi research as Merck shutters R&D outpost. News

> Ariad boosted by news of Merck's application for ridaforolimus. Item

> Immunotherapy developer Argos takes a run at $86M IPO. Report

> CRO Chiltern goes up on auction block. Story

Biotech IT News

> A free app to bypass Myriad's gene patent: How can gaming aid life science researchers? Item

> Survey: Developers stumble when projecting trial costs. Piece

> Sequencing giant BGI shoots for the cloud. More

> FDA eyes "value" of modeling used in drug development. News

> Ontario cancer group to get $40M deal, expand bioinformatics effort. Article

> PharmaPros teams up with Soltex, extends pharma reach. Story

> Eyeing big pharma needs, Icon xplains clinical tech buyout. Report

Medical Devices News

> CR Bard CFO to retire. Piece

> FDA Oks Medtronic study of second-generation pacing system. More

> World Heart to stop Levacore deelopment, reduce workforce. News

> Baxter establishs $200M venture arm. Report

> Boston Scientific to cut 1,400 jobs. Story

> Intuity closes $76M Series D financing. Article

> IOM report fuels debate over device reviews. More

And Finally... On second thought, human genes can be patented, a U.S. appeals court found. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.